Gastroparesis - Market Insights, Epidemiology and Market Forecast-2027 Market Report; Launched via MarketResearchReports.com
MarketResearchReprots.com has announced the addition of “Gastroparesis - Market Insights, Epidemiology and Market Forecast-2027” research report to their website www.MarketResearchReports.com
Lewes, DE -- (SBWire) -- 08/09/2018 --Gastroparesis - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Gastroparesis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Gastroparesis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
Study Period: 2016-2027
Gastroparesis - Disease Understanding and Treatment Algorithm
According to International Foundation for Functional Gastrointestinal Disorders (IFFGD), Gastroparesis is also called delayed gastric emptying. It is a condition that affects the normal spontaneous movement of the muscles (motility) in stomach. It is defined as a combination of chronic dyspeptic symptoms and delayed emptying of a solid test meal. It remains a difficult-to-treat disorder with a significant impact on quality of life.
The Publisher Gastroparesis market report gives the thorough understanding of the Gastroparesis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Gastroparesis in the US, Europe, and Japan.
The Gastroparesis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Publisher report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Gender Specific Prevalence, Severity based prevalence and Diagnosed and treatable population] scenario of Gastroparesis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to Digestive Diseases Center, Gastroparesis affects more than 1.5 million Americans, with approximately 100,000 suffering from a severe form of the disorder and standard medical therapy fails to relieve symptoms in approximately 30,000 of these patients.
At least 20 percent of people with type 1 diabetes develop gastroparesis. The disease also occurs in people with type 2 diabetes, although less often.
Gastroparesis Drug Chapters
This segment of the Gastroparesis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The market size of Gastroparesis is mainly accounted by the therapeutic categories of prokinetic (promotility) agents (such as Metoclopramide, Domperidone, Erythromycin, Cisapride), antiemetic agents and Botulinum Toxin Injection (nerve blocking agent). Only one drug, Metoclopramide is approved by the U.S. Food and Drug Administration (FDA) for the treatment of gastroparesis. Off-label use is the permissible practice by doctors to prescribe medications for other than their FDA approved intended indications.
Gastroparesis Market Outlook
The Gastroparesis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Expected launch of emerging therapies such as VLY-686 (Vanda Pharmaceuticals), TAK-906 (Takeda Pharaceutical), Relamorelin (Allergan), TD-8954 (Theravance Biopharma) and other treatments, are shall lead to a significant increase in the market size during the forecast period [2018-2027].
Gastroparesis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Gastroparesis Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Gastroparesis Report Key Strengths
- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Sub-type Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Gastroparesis Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This Publisher report will help to develop Business Strategies by understanding the trends shaping and driving Gastroparesis market
- Organize sales and marketing efforts by identifying the best opportunities for Gastroparesis market
- To understand the future market competition in the Gastroparesis market.
Spanning over 120 pages "Gastroparesis - Market Insights, Epidemiology and Market Forecast-2027" report covers Report Introduction, Gastroparesis Market Overview at a Glance, Disease Background and Overview: Gastroparesis, Epidemiology and Patient Population, Epidemiology of Gastroparesis& Night Sweats by Countries (2016-2027), Treatments & Medical Practices, Marketed Product, Emerging Therapies, Gastroparesis Market Size, 7MM: Country-Wise Market Analysis, Market Drivers, Market Barriers, Report Methodology.
Please visit this link for more details: https://www.marketresearchreports.com/delveinsight/gastroparesis-market-insights-epidemiology-and-market-forecast-2027
Find all Drug Pipeline Reports at: https://www.marketresearchreports.com/drug-pipeline
For related reports please visit: https://www.marketresearchreports.com/search/site/Gastroparesis
Read our Interactive Market Research Blog
MarketResearchReprots.com is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.
Contact us for your market research requirements: https://www.marketresearchreports.com/contact
Media Relations Contact
Director - Operations
View this press release online at: http://rwire.com/1024746